EcoDrugPlus

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSOTSG00005018361
Gene Symbol: GUCY1B1
1 Cross references
202 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSOTSG00005014372
Gene Symbol: GUCY1B1
1 Cross references
203 Possible Orthologues:

Guanylate Cyclase Soluble Subunit Alpha-1-Like

Ensembl ID : ENSOTSG00005014365
Gene Symbol: LOC112234399
3 Cross references
195 Possible Orthologues:

Guanylate Cyclase Soluble Subunit Alpha-1-Like

Ensembl ID : ENSOTSG00005037177
Gene Symbol: LOC112234399
3 Cross references
203 Possible Orthologues:

Heat Shock Protein Hsp 90-Beta

Ensembl ID : ENSOTSG00005002318
Gene Symbol: LOC112217445
3 Cross references
333 Possible Orthologues:

Heat Shock Protein Hsp 90-Beta-Like

Ensembl ID : ENSOTSG00005029732
Gene Symbol: LOC112249973
3 Cross references
333 Possible Orthologues:

Hepatocyte Growth Factor Receptor-Like

Ensembl ID : ENSOTSG00005035985
Gene Symbol: LOC112252650
3 Cross references
200 Possible Orthologues:

High Affinity Camp-Specific 3',5'-Cyclic Phosphodiesterase 7a-Like

Ensembl ID : ENSOTSG00005044994
Gene Symbol: LOC112215382
3 Cross references
219 Possible Orthologues:

High Affinity Camp-Specific 3',5'-Cyclic Phosphodiesterase 7a-Like

Ensembl ID : ENSOTSG00005044495
Gene Symbol: LOC112215382
3 Cross references
219 Possible Orthologues:

High Affinity Camp-Specific 3',5'-Cyclic Phosphodiesterase 7a-Like

Ensembl ID : ENSOTSG00005031369
Gene Symbol: LOC112233613
3 Cross references
219 Possible Orthologues:

High Mobility Group Box 1b

Ensembl ID : ENSOTSG00005033284
Gene Symbol: HMGB1B
1 Cross references
503 Possible Orthologues:

High Mobility Group Box 1b

Ensembl ID : ENSOTSG00005014563
Gene Symbol: HMGB1B
1 Cross references
503 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).